New antibiotic candidate JKN2501 begins first human safety tests
NCT ID NCT07207291
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 31 times
Summary
This early-stage study is testing a new drug called JKN2501 in 66 healthy adults to see if it is safe and how the body processes it. The drug is being developed to fight bacterial infections like urinary tract and lung infections. Participants will receive either the drug or a placebo, and researchers will monitor for side effects and measure drug levels in blood, urine, and stool. This study does not aim to treat any disease; it is a first step to gather safety information for future trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY TRACT INFECTIONS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Third hospital of Changsha
RECRUITINGChangsha, Hunan, 410035, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.